Geron Corporation (NASDAQ: GERN) has dosed first patient in IMproveMF study evaluating imetelstat in combination with ruxolitinib for patients with frontline myelofibrosis (MF).
Geron (NASDAQ:GERN) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 22.22 percent increase over losses of $(0.09) per share from the same
Companies Reporting Before The Bell
• Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.
Gainers
Direct Digital Holdings, Inc. (NASDAQ: DRCT) shares jumped 82.6% to $4.71 after the company reported a year over year increase in Q4 sales results and issued Q1 sales guidance above analyst estimates.
Gainers
Adagio Therapeutics (NASDAQ:ADGI) shares increased by 52.2% to $5.86 during Wednesday's pre-market session. The company's market cap stands at $651.9 million.
Geron (NASDAQ:GERN) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
Geron missed estimated earnings by 25.0%, reporting an EPS of $-0.1 versus an estimate of $-0.08.